Chugai Pharmaceutical Co., Ltd.
Chugai Adopts Snowflake Data Cloud to Accelerate Internal Data Utilization Across the Enterprise
Snowflake brings its global experience and background in healthcare and life sciences to Japan for the first time
TOKYO, April 21, 2022 — Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) and Snowflake announce that Chugai has adopted the Snowflake Data Cloud, a data cloud platform provided by Snowflake.
The Snowflake Data Cloud is a cloud-based data platform that provides data governance and security and enables use of the latest data across divisions and projects. Chugai will drive innovation by accelerating enterprise-wide use of data held by every function and division.
The pharmaceutical industry processes an enormous amount of complex data across the entire value chain, from research and development to the commercialization of pharmaceutical products. The major challenge is to build a unifying environment that allows the mutual use of internal data to accelerate innovation. Chugai is driving the integration and use of data held by divisions and projects with “strengthening the digital platform” as one of the core strategies of the DX strategy CHUGAI DIGITAL VISION 2030.To improve and accelerate the creation of new innovative drugs, the company, including the Research division, needed to adapt to a safe and fast analysis environment for a large amount of sensitive data. A platform that integrates data across organizations was also needed to further improve the delivery of information to healthcare providers.
Snowflake offers the Data Cloud to help businesses and organizations efficiently accumulate, analyze, and use vast amounts of internal and external data. Chugai chose Snowflake as their preferred data platform. Snowflake enables Chugai to mobilize its data with the Snowflake Healthcare and Life Sciences Data Cloud to unite siled data, securely discover and share data, and run various analytical workloads. Additionally, Snowflake’s connectivity that does not rely on a single public cloud enables safe, secure, and efficient access, which is another reason why Chugai chose Snowflake.
Chugai will integrate data held by departments and projects on the Snowflake Data Cloud and connect it to Chugai’s own Chugai Scientific Infrastructure (CSI) digital computing platform to develop an enterprise-scale analytics environment. . This should strengthen data governance and reduce security risks and costs. At the drug discovery function level, it is expected to help maximize data value and improve productivity, including accelerated evaluation of drug candidates by simulation based on large amount of data and reliable experimental hypotheses, and multimodal analyses. At the value delivery function level, Chugai aims to advance an innovative customer engagement model to deliver the value customers need through optimal communication. The company will integrate and use internal data to predict efficacy and safety to create unique evidence contributing to personalized medicine.
[Use of data and analytics environment across company]
[Data use in drug discovery]
This announcement represents the first case in Japan for Snowflake in healthcare and life sciences. Significantly, Snowflake was selected as the data integration platform for Chugai, a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. In healthcare and life sciences, the demands are high, including the highest level of data security and governance. Snowflake offers the Data Cloud to help providers optimize care delivery, improve clinical and operational decision making, and accelerate clinical research and time to market. Building on its global track record, Snowflake will bring its experience, know-how and enterprise-grade support to Japan.
Pharmaceutical companies have the common challenge of creating an environment that enables the use of internal data to further accelerate innovation. By connecting the Snowflake Data Cloud, which enables unified data management, and CSI, our own digital computing platform, we can create an environment for security and rapid analysis of huge data. With “strengthening the digital platform” as one of the core strategies of our DIGITAL CHUGAIVISION 2030,we will accelerate the use of internal data across the enterprise, including the drug discovery and value creation function.
Satoko Shisai, Executive Vice President, Head of Digital Transformation Unit, Chugai
We are delighted to announce the first deployment case in healthcare and life sciences in Japan. We are very honored to offer our Data Cloud to Chugai, a leading healthcare company in Japan. Snowflake helps Chugai drive healthcare innovation and deliver even better outcomes for patients and all stakeholders.
Hidetoshi Tojo, Japan General Manager, Snowflake
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that can address unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining its management autonomy and independence, Chugai is an important member of the Roche Group. Additional information is available at https://www.chugaI-pharm.co.jp/english/.
About the snowflake
Snowflake enables every organization to mobilize their data with the Snowflake Data Cloud. Customers use the Data Cloud to unite siled data, securely discover and share data, and run various analytical workloads. Wherever the data or users reside, Snowflake delivers a single data experience that spans multiple clouds and geographies. Thousands of customers across many industries, including 241 of the 2021 Fortune 500 and 488 of the 2021 Forbes Global 2000 (G2K) as of January 31, 2022, use Snowflake Data Cloud to power their businesses. Learn more about snowflake.com.
Chugai Pharmaceutical Co., Ltd. Corporate Communications Department
Media Relations Group
Such. : +81-(0)3-3273-0881 Investor Relations Group Tel. : +81-(0)3-3273-0554
japan snowflake Medias
Yuki NakajimaMarketing[email protected]